Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Recombinant Tuberculosis Vaccine AEC/BC02 in Latent Infection
NCT05284812Phase 2Suspended
- Sponsor
- Zhifei Biological
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AEC/BC02 in Tuberculosis (TB), sponsored by Zhifei Biological. Started Feb 2022; status: suspended.
02
Drugs
AEC/BC02
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05284812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284812.